Publikationen, an denen er mitarbeitet José Alberto Arranz Caso (11)

2022

  1. Discovering HIV related information by means of association rules and machine learning

    Scientific Reports, Vol. 12, Núm. 1

  2. Epidemiological trends of HIV/HCV coinfection in Spain, 2015–2019

    HIV Medicine, Vol. 23, Núm. 7, pp. 705-716

  3. Predictors of low-level HIV viraemia and virological failure in the era of integrase inhibitors: A Spanish nationwide cohort

    HIV Medicine, Vol. 23, Núm. 8, pp. 825-836

2021

  1. COVID-19 in hospitalized HIV-positive and HIV-negative patients: A matched study

    HIV Medicine, Vol. 22, Núm. 9, pp. 867-876

2020

  1. Effects of first-line antiretroviral therapy on the CD4/CD8 ratio and CD8 cell counts in CoRIS: a prospective multicentre cohort study

    The Lancet HIV, Vol. 7, Núm. 8, pp. e565-e573

2016

  1. Human immunodeficiency virus/hepatitis C virus coinfection in Spain: Prevalence and patient characteristics

    Open Forum Infectious Diseases, Vol. 3, Núm. 2

2009

  1. Risk factors for loss of virological suppression in patients receiving lopinavir/ritonavir monotherapy for maintenance of HIV suppression

    Antiviral Therapy, Vol. 14, Núm. 2, pp. 195-201

2008

  1. Patients' perception and effectiveness of a treatment containing enfuvirtide when used in HIV-infected patients without very advanced disease

    HIV Clinical Trials, Vol. 9, Núm. 2, pp. 83-90

2005

  1. A randomized controlled trial investigating the efficacy and safety of switching from a protease inhibitor to nevirapine in patients with undetectable viral load

    HIV Medicine, Vol. 6, Núm. 5, pp. 353-359

2004

  1. Long-term efficacy and safety of protease inhibitor switching to nevirapine in HIV-infected patients with undetectable virus load

    Clinical Infectious Diseases, Vol. 39, Núm. 7, pp. 1024-1029

  2. Treatment of HIV-infected patients with a combination of efavirenz, nevirapine and nucleoside reverse transcriptase inhibitors

    HIV Medicine, Vol. 5, Núm. 2, pp. 128-129